Previous 10 | Next 10 |
RedHill Biopharma (RDHL) saw its Q1 net loss narrow 6% to $22.9M as prescription volumes for its marketed drugs rose.The company beat on EPS but missed on revenues.New prescriptions of Movantik (naloxegol) for opioid-induced constipation increased 4% compared to the year-ago period.In Fe...
RedHill (RDHL): Q1 GAAP EPS of $0.05 beats by $0.29.Revenue of $20.57M (+1840.6% Y/Y) misses by $2.13M.Press Release For further details see: RedHill EPS beats by $0.29, misses on revenue
RedHill Biopharma Reports First Quarter 2021 Financial Results and Operational Highlights Q1/2021 net revenues of approximately $20.6 million compared to $1.1 million for Q1/2020; Cash balance[i] of approximately $92 million as of March 31, 2021, compared to approximately $115 m...
RedHill Biopharma (RDHL) announces the receipt of two Notices of Allowance from the U.S. Patent and Trademark Office ((USPTO)) covering opaganib and RHB-107 (upamostat) as methods for the treatment of COVID-19.Both opaganib and RHB-107 are novel COVID-19 therapeutic candidates,...
RedHill Biopharma Receives Allowances for U.S. Patent Applications Covering Opaganib and RHB-107 for COVID-19 The two patents protect opaganib and RHB-107 for the treatment of COVID-19 until at least 2041 once granted Enrollment in opaganib's global Phase 2/3 study in hospit...
RedHill Biopharma Presents Analyses of Movantik Onset of Action and Symptom Improvement at DDW 2021 Two new analyses of Movantik® (naloxegol) data, from almost 900 patients, were presented at Digestive Disease Week 2021 evaluating the onset of action and symptom improvement...
RedHill Biopharma Presents a New Travelers' Diarrhea Clinical Severity Classification Tool and its Use in Aemcolo Efficacy Analysis at DDW 2021 New Travelers' Diarrhea (TD) severity classification tool, developed with the University of Texas Houston School of Public Health, prov...
RedHill Biopharma to Host First Quarter 2021 Financial Results and Operational Highlights Webcast on May 27, 2021 PR Newswire TEL AVIV, Israel and RALEIGH, N.C. , May 20, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Compan...
RedHill Biopharma ([[RDHL]] +7.1%) is “building the next leading gastroenterology-focused specialty pharmaceuticals franchise in the U.S.,” says H.C. Wainwright analyst Raghuram Selvaraju initiating the coverage on the stock with a buy rating.The price target of $23.00 per share...
Stealth BioTherapeutics (MITO) +31% on Q1 results.Ultralife Corporation (ULBI) +22% on new contract from U.S. Army.China HGS Real Estate Inc. (HGSH) +14% on Q2 results.XpresSpa Group (XSPA) +9% on Q1 results.Reliance Global Group (RELI) +8%.Express (EXPR) +7%.Eloxx Pharmac...
News, Short Squeeze, Breakout and More Instantly...
Redhill Biopharma Ltd. Company Name:
RDHL Stock Symbol:
NASDAQ Market:
Redhill Biopharma Ltd. Website:
RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia® Lien PR Newswire TEL-AVIV, Israel and RALEIGH, NC , July 22, 2024 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biophar...
RedHill Biopharma Terminates License Agreement for Aemcolo® PR Newswire TEL-AVIV, Israel and RALEIGH, NC , July 9, 2024 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today ...
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...